|
|
 | | | |
- close
- close
- close
- close
| |||||||||
This excerpt taken from the ELN 20-F filed Mar 30, 2006. HOSPITAL
BUSINESS AND PRODUCTS
Severe bacterial infections remain a major medical concern, even
more so with the rise in resistance and fewer available
therapies. We market two products that treat severe bacterial
infections, each designed to address specific medical needs
within the hospital market. Distinct from the community market,
the hospital market is highly specialized and often relies on a
team of healthcare professionals that influences the
decision-making process. We are committed to meeting the needs
of the infectious disease and critical care community within the
hospital market.
The Hospital Business actively maintains relationships with
1,035 hospitals throughout the United States, each characterized
by unique and complex decision-making processes. Approximately
550 of these are leading academic-teaching institutions. Our
hospital sales force maintains key relationships with doctors
and other healthcare professionals in the areas of infectious
disease, critical care, pulmonary, emergency and pharmacy; and
frequently interacts with oncologists.
Maxipime
We licensed the U.S. marketing rights to Maxipime
from Bristol-Myers Squibb Company (Bristol-Myers) in January
1999. Maxipime is a fourth-generation injectable
cephalosporin antibiotic used to treat patients with serious
and/or
life-threatening infections. Pulmonologists, infectious disease
specialists, emergency medicine specialists, surgeons, internal
medicine physicians, hematologists and oncologists prescribe
Maxipime for patients with severe infections requiring
hospitalization, such as pneumonia, urinary tract infection and
febrile neutropenia. Attributes of Maxipime are its broad
spectrum of activity, including activity against many pathogens
resistant to other antibiotics, ease of use and favorable
pharmaco-economic profile. Revenue from sales of Maxipime
amounted to $140.3 million for 2005. The basic
U.S. patent on Maxipime expires in March 2007.
However, two other U.S. patents covering Maxipime
formulations may provide protection until February 2008.
Azactam
We licensed the U.S. marketing rights to this injectable
antibiotic from Bristol-Myers in January 1999. Azactam is
a monobactam and is principally used by surgeons, infectious
disease specialists and internal medicine physicians to treat
pneumonia, post-surgical infections and septicemia. Revenue from
sales of Azactam totalled $57.7 million for 2005.
The basic U.S. patent on Azactam expired in October
2005. To date, no generic Azactam product has been
approved. However, we expect that generic competition to
Azactam will emerge in 2006.
Please refer to Item 5.A “Operating Results” for
additional information concerning our revenue by category for
2005, 2004 and 2003.
Table of Contents
Table of Contents
|
| |||||||
